Goran Forsberg, PhDChief Executive Officer at Cantargia ABSpeaker
Profile
Göran Forsberg has been CEO for Cantargia AB since 2014. Cantargia develops antibodies for the treatment of
cancer and autoimmunity/inflammatory diseases. The lead project, CAN04, is in phase I/IIa clinical
development focused on non-small cell lung cancer and pancreatic cancer. Dr Forsberg has a PhD in
biochemistry Royal Institute of Technology, Stockholm, Sweden, is an associate professor and author of over 40
scientific publications. Previous positions include KabiGen, Pharmacia, Active Biotech and University of
Adelaide.